# 2025-21191: Company Seeks Permission to Import Mystery Controlled Substances

2025-21191, Importer of Controlled Substances Application: Noramco, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-11-26, effective Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 26, 2025. Such persons may also file a written request for a hearing on the application on or before December 26, 2025. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21191
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21191
- Title: Importer of Controlled Substances Application: Noramco
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 54371
- Published: 2025-11-26
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 26, 2025. Such persons may also file a written request for a hearing on the application on or before December 26, 2025.
- Comments close: 2025-12-26
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Company Seeks Permission to Import Mystery Controlled Substances

## Summary

Noramco wants to become an official importer of some controlled substances like marijuana and methadone. If you’re a registered manufacturer or interested party, you have until December 26, 2025, to share your thoughts or ask for a hearing. This move could affect companies dealing with these drugs and might impact how these substances enter the U.S.

## Abstract

Noramco has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Noramco applied to import listed controlled substances: mixed, low. On September 22, 2025, Noramco applied to be registered as an importer for multiple controlled substances, including Gamma Hydroxybutyric Acid (code 2010, Schedule I), Marihuana (7360, Schedule I), Tetrahydrocannabinols (7370, Schedule I), Methadone-Intermediate (9254, Schedule II), and various opi…
- Planned import of Poppy Straw Concentrate (9670): benefit, low. Noramco plans to import Poppy Straw Concentrate (drug code 9670) to bulk manufacture other controlled substances for distribution to its customers. This planned import is specifically for bulk manufacturing use and distribution to Noramco's customers.
- Planned import of Tapentadol intermediate (9780): benefit, low. Noramco plans to import an intermediate form of Tapentadol (drug code 9780) to bulk manufacture Tapentadol for distribution to its customers. The application states the intermediate will be used for bulk manufacture rather than finished product importation.
- Synthetic CBD and THC import limits for marijuana codes: cost, low. For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Noramco's application says it plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. The notice also states that no other activities for these drug codes are authorized under this registration.
- Finished dosage forms not authorized for import: cost, low. The notice states that authorization will not extend to the import of Food and Drug Administration (FDA) approved or non-approved finished dosage forms for commercial sale. The registration is limited to activities consistent with 21 U.S.C. 952(a)(2).
- Comment and hearing request deadline: Dec 26, 2025: mixed, low. Registered bulk manufacturers of the affected classes and other applicants may submit electronic comments, objections, or a written request for a hearing on Noramco's application on or before December 26, 2025. Comments must be submitted via regulations.gov; hearing requests have specified mailing…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-21191 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/26/2025-21191/importer-of-controlled-substances-application-noramco)
- [2025-21191 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-26/pdf/2025-21191.pdf)

## Related
- [Previous: 2025-21190, Bulk Manufacturer of Controlled Substances Application: National Center for Nat…](https://policyrisk.com/federal-register/2025-21190)
- [Next: 2025-21192, Bulk Manufacturer of Controlled Substances Application: Noramco](https://policyrisk.com/federal-register/2025-21192)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21191 (as of 2026-06-08).
